{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T09:05:41Z","timestamp":1784106341131,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,8,5]]},"DOI":"10.1038\/s41416-026-03459-1","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:06:17Z","timestamp":1777547177000},"page":"436-444","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase I trial of a heat-conditioned tumor lysate vaccine (TRIMELVax) in anti-PD-1 refractory melanoma: safety and immunological aspects (NCT06556004)"],"prefix":"10.1038","volume":"135","author":[{"given":"Roberto","family":"Estay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anal\u00eda","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabi\u00e1n","family":"Tempio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rebolledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Contalba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Bustos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Pereda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Alejandra","family":"Gleisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferm\u00edn E.","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Tittarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0432-710X","authenticated-orcid":false,"given":"Adnane","family":"Achour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Lladser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda In\u00e9s","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1848-5697","authenticated-orcid":false,"given":"Flavio","family":"Salazar-Onfray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1744-2038","authenticated-orcid":false,"given":"Mercedes N.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"3459_CR1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350\u20135.","journal-title":"Science"},{"key":"3459_CR2","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","volume":"22","author":"I Pires da Silva","year":"2021","unstructured":"Pires da Silva I, Ahmed T, Reijers ILM, Weppler AM, Warner AB, Patrinely JR, et al. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol. 2021;22:836\u201347.","journal-title":"Lancet Oncol"},{"key":"3459_CR3","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/S0140-6736(20)32598-8","volume":"397","author":"F Meric-Bernstam","year":"2021","unstructured":"Meric-Bernstam F, Larkin J, Tabernero J, Bonini C. Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet. 2021;397:1010\u201322.","journal-title":"Lancet"},{"key":"3459_CR4","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/2326-6066.CIR-20-0586","volume":"10","author":"M Karasarides","year":"2022","unstructured":"Karasarides M, Cogdill AP, Robbins PB, Bowden M, Burton EM, Butterfield LH, et al. Hallmarks of resistance to immune-checkpoint inhibitors. Cancer Immunol Res. 2022;10:372\u201383.","journal-title":"Cancer Immunol Res"},{"key":"3459_CR5","doi-asserted-by":"publisher","first-page":"111989","DOI":"10.1016\/j.intimp.2024.111989","volume":"132","author":"R Wang","year":"2024","unstructured":"Wang R, Chen Y, Xie Y, Ma X, Liu Y. Deciphering and overcoming anti-PD-1 resistance in melanoma. Int Immunopharmacol. 2024;132:111989.","journal-title":"Int Immunopharmacol"},{"key":"3459_CR6","doi-asserted-by":"publisher","first-page":"e006398","DOI":"10.1136\/jitc-2022-006398","volume":"11","author":"J Naidoo","year":"2023","unstructured":"Naidoo J, Murphy C, Atkins MB, Brahmer JR, Champiat S, Felquate D, et al. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events terminology. J Immunother Cancer. 2023;11:e006398.","journal-title":"J Immunother Cancer"},{"key":"3459_CR7","first-page":"1657","volume":"13","author":"W Shalata","year":"2023","unstructured":"Shalata W, Yakobson A, Cohen AY, Goldstein I, Saleh OA, Dudnik Y, et al. Unexpected adverse events of immune checkpoint inhibitors. Life (Basel). 2023;13:1657.","journal-title":"Life (Basel)"},{"key":"3459_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejca.2021.03.010","volume":"149","author":"E Ghisoni","year":"2021","unstructured":"Ghisoni E, Wicky A, Bouchaab H, Imbimbo M, Delyon J, Moura BG, et al. Late-onset and long-lasting immune-related adverse events from immune checkpoint inhibitors: an overlooked aspect in immunotherapy. Eur J Cancer. 2021;149:153\u201364.","journal-title":"Eur J Cancer"},{"key":"3459_CR9","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/JLB.5BT0119-016R","volume":"108","author":"D Shae","year":"2020","unstructured":"Shae D, Baljon JJ, Wehbe M, Becker KW, Sheehy TL, Wilson JT. At the bench: engineering the next generation of cancer vaccines. J Leukoc Biol. 2020;108:1435\u201353.","journal-title":"J Leukoc Biol"},{"key":"3459_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21:360\u201378.","journal-title":"Nat Rev Cancer"},{"key":"3459_CR11","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41573-020-0074-8","volume":"19","author":"A Harari","year":"2020","unstructured":"Harari A, Graciotti M, Bassani-Sternberg M, Kandalaft LE. Antitumour dendritic cell vaccination in a priming and boosting approach. Nat Rev Drug Discov. 2020;19:635\u201352.","journal-title":"Nat Rev Drug Discov"},{"key":"3459_CR12","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41416-023-02327-6","volume":"129","author":"A P\u00e9rez-Ba\u00f1os","year":"2023","unstructured":"P\u00e9rez-Ba\u00f1os A, Gleisner MA, Flores I, Pereda C, Navarrete M, Araya JP, et al. Whole tumour cell-based vaccines: tuning the instruments to orchestrate an optimal antitumour immune response. Br J Cancer. 2023;129:572\u201385.","journal-title":"Br J Cancer"},{"key":"3459_CR13","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3390\/cells12172159","volume":"12","author":"M Kaczmarek","year":"2023","unstructured":"Kaczmarek M, Pozna\u0144ska J, Fechner F, Michalska N, Paszkowska S, Napierala A, et al. Cancer vaccine therapeutics: limitations and effectiveness \u2013 a literature review. Cells. 2023;12:2159.","journal-title":"Cells"},{"key":"3459_CR14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/j.1365-2249.2005.02948.x","volume":"142","author":"A Escobar","year":"2005","unstructured":"Escobar A, L\u00f3pez M, Serrano A, Ram\u00edrez M, P\u00e9rez C, Aguirre A, et al. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol. 2005;142:555\u201368.","journal-title":"Clin Exp Immunol"},{"key":"3459_CR15","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1200\/JCO.2008.18.0794","volume":"27","author":"MN L\u00f3pez","year":"2009","unstructured":"L\u00f3pez MN, Pereda C, Segal G, Mu\u00f1oz L, Aguilera R, Gonz\u00e1lez FE, et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumour-specific delayed type IV hypersensitivity response and reduction of tumour TGF-\u03b2-expressing T cells. J Clin Oncol. 2009;27:945\u201352.","journal-title":"J Clin Oncol"},{"key":"3459_CR16","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1158\/1078-0432.CCR-10-2384","volume":"17","author":"R Aguilera","year":"2011","unstructured":"Aguilera R, Saffie C, Tittarelli A, Gonz\u00e1lez FE, Ram\u00edrez M, Reyes D, et al. Heat-shock induction of tumour-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells. Clin Cancer Res. 2011;17:2474\u201383.","journal-title":"Clin Cancer Res"},{"key":"3459_CR17","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/bjc.2013.494","volume":"109","author":"D Reyes","year":"2013","unstructured":"Reyes D, Salazar L, Espinoza E, Pereda C, Castell\u00f3n E, Valdevenito R, et al. Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients. Br J Cancer. 2013;109:1488\u201397.","journal-title":"Br J Cancer"},{"key":"3459_CR18","doi-asserted-by":"publisher","first-page":"e000999","DOI":"10.1136\/jitc-2020-000999","volume":"8","author":"MA Gleisner","year":"2020","unstructured":"Gleisner MA, Pereda C, Tittarelli A, Navarrete M, Fuentes C, \u00c1valos I, et al. A heat-shocked melanoma cell lysate vaccine enhances tumour infiltration by prototypic effector T cells inhibiting tumour growth. J Immunother Cancer. 2020;8:e000999.","journal-title":"J Immunother Cancer"},{"key":"3459_CR19","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1002\/eji.202149225","volume":"51","author":"J Villar","year":"2021","unstructured":"Villar J, Salazar ML, Jim\u00e9nez JM, Del Campo M, Manubens A, Gleisner MA, et al. C-type lectin receptors MR and DC-SIGN are involved in recognition of hemocyanins, shaping their immunostimulatory effects on human dendritic cells. Eur J Immunol. 2021;51:1715\u201331.","journal-title":"Eur J Immunol"},{"key":"3459_CR20","doi-asserted-by":"publisher","first-page":"26134","DOI":"10.1074\/jbc.M400903200","volume":"279","author":"P De Ioannes","year":"2004","unstructured":"De Ioannes P, Moltedo B, Oliva H, Pacheco R, Faunes F, De Ioannes AE, et al. Hemocyanin of the molluscan Concholepas concholepas exhibits an unusual heterodecameric array of subunits. J Biol Chem. 2004;279:26134\u201342.","journal-title":"J Biol Chem"},{"key":"3459_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"3459_CR22","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 (2017)."},{"key":"3459_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547:217\u201321.","journal-title":"Nature"},{"key":"3459_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","volume":"585","author":"U Sahin","year":"2020","unstructured":"Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585:107\u201312.","journal-title":"Nature"},{"key":"3459_CR25","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","volume":"576","author":"CS Jansen","year":"2019","unstructured":"Jansen CS, Prokhnevska N, Master VA, Sanda MG, Carlisle JW, Bilen MA, et al. An intratumoral niche maintains and differentiates stem-like CD8 T cells. Nature. 2019;576:465\u201370.","journal-title":"Nature"},{"key":"3459_CR26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, et al. Intratumoral TCF1\u207aPD-1\u207aCD8\u207a T cells with stem-like properties promote tumour control in response to vaccination and checkpoint blockade immunotherapy. Immunity. 2019;50:195\u2013211.e10.","journal-title":"Immunity"},{"key":"3459_CR27","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/s41568-025-00858-z","volume":"25","author":"M Dolan","year":"2025","unstructured":"Dolan M, Libby KA, Ringel AE, van Galen P, McAllister SS. Ageing, immune fitness and cancer. Nat Rev Cancer. 2025;25:848\u201372.","journal-title":"Nat Rev Cancer"},{"key":"3459_CR28","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345\u201356.","journal-title":"N Engl J Med"},{"key":"3459_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.22.00221","volume":"41","author":"A Arance","year":"2023","unstructured":"Arance A, de la Cruz-Merino L, Petrella TM, Jamal R, Ny L, Carneiro A, et al. Phase II LEAP-004: lenvatinib plus pembrolizumab for melanoma with confirmed progression on PD-1\/PD-L1 inhibitors. J Clin Oncol. 2023;41:75\u201385.","journal-title":"J Clin Oncol"},{"key":"3459_CR30","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","volume":"29","author":"A VanderWalde","year":"2023","unstructured":"VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO, et al. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med. 2023;29:2278\u201385.","journal-title":"Nat Med"},{"key":"3459_CR31","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1200\/JCO.21.00079","volume":"39","author":"DJ Olson","year":"2021","unstructured":"Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, et al. Pembrolizumab plus ipilimumab following anti-PD-1\/L1 failure in melanoma. J Clin Oncol. 2021;39:2647\u201355.","journal-title":"J Clin Oncol"},{"key":"3459_CR32","doi-asserted-by":"publisher","first-page":"8035","DOI":"10.3390\/ijms22158035","volume":"22","author":"CG Kim","year":"2021","unstructured":"Kim CG, Sang YB, Lee JH, Chon HJ. Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach. Int J Mol Sci. 2021;22:8035 27.","journal-title":"Int J Mol Sci"},{"key":"3459_CR33","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41423-025-01316-4","volume":"22","author":"K Peng","year":"2025","unstructured":"Peng K, Zhao X, Fu YX, Liang Y. Eliciting antitumor immunity via therapeutic cancer vaccines. Cell Mol Immunol. 2025;22:840\u201368.","journal-title":"Cell Mol Immunol"},{"key":"3459_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105068","volume":"217","author":"M Rota","year":"2026","unstructured":"Rota M, Torresan I, Palmerio S, Tasselli E, Rossi A, Zivi A, et al. The role of therapeutic cancer vaccines in the modern immunotherapy era: State of the art with recent progress and future challenges. Crit Rev Oncol Hematol. 2026;217:105068.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3459_CR35","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.trecan.2024.06.003","volume":"10","author":"A Brandenburg","year":"2024","unstructured":"Brandenburg A, Heine A, Brossart P. Next-generation cancer vaccines and emerging immunotherapy combinations. Trends Cancer. 2024;10:749\u201369.","journal-title":"Trends Cancer"},{"key":"3459_CR36","doi-asserted-by":"publisher","first-page":"e008817","DOI":"10.1136\/jitc-2024-008817","volume":"12","author":"SK M\u00f8rk","year":"2024","unstructured":"M\u00f8rk SK, Skadborg SK, Albieri B, Draghi A, Bol K, Kadivar M, et al. Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma. J Immunother Cancer. 2024;12:e008817.","journal-title":"J Immunother Cancer"},{"key":"3459_CR37","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41586-025-09655-y","volume":"647","author":"AJ Grippin","year":"2025","unstructured":"Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature. 2025;647:488\u201397.","journal-title":"Nature"},{"key":"3459_CR38","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.3390\/cancers15143564","volume":"15","author":"C Nardin","year":"2023","unstructured":"Nardin C, Hennemann A, Diallo K, Funck-Brentano E, Puzenat E, Heidelberger V, et al. Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients\u2019 Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Canc\u00e9rologie Cutan\u00e9e, GCC). Cancers (Basel). 2023;15:3564.","journal-title":"Cancers (Basel)"},{"key":"3459_CR39","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ejca.2021.07.002","volume":"155","author":"A Zaremba","year":"2021","unstructured":"Zaremba A, Eggermont AMM, Robert C, Dummer R, Ugurel S, Livingstone E, et al. The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. Eur J Cancer. 2021;155:268\u201380.","journal-title":"Eur J Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03459-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03459-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03459-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T08:30:44Z","timestamp":1784104244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03459-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8,5]]}},"alternative-id":["3459"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03459-1","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest. The funders had no role in the study\u2019s design, data collection, analysis, or interpretation, nor in the writing of the manuscript or the decision to publish the results.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethical Committee for Human Research of the University of Chile, Faculty of Medicine (363\/290102), and the Ethical Committee for Human Research of the University of Chile\u2019s Clinical Hospital (227\/280803). Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors have reviewed and approved the final version of the manuscript and consent to its submission and potential publication.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}]}}